Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022 Aug;10(8):e004904. doi: 10.1136/jitc-2022-004904
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, Chiu K, Boller E, Bharmal M. Real-world clinical outcomes among patients with advanced Merkel cell carcinoma treated with avelumab in academic medical centers in the United States. Poster presented at the SITC 2021 36th Anniversary Annual Meeting; November 9, 2021. Washington, DC. [abstract] J Immunother Cancer. 2021 Nov; 9(Suppl 2):A658.
Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0
Camprodon-Rosanas E, Ribas-Fito N, Batlle-Vila S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Sluggish cognitive tempo: sociodemographic, behavioral, and clinical characteristics in a population of Catalan school children. J Atten Disord. 2017 Jun;21(8):632-41. doi: 10.1177/1087054716652477
Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245
Vilor-Tejedor N, Alemany S, Forns J, Caceres A, Murcia M, Macia D, Pujol J, Sunyer J, Gonzalez JR. Assessment of susceptibility risk factors for ADHD in imaging genetic studies. J Atten Disord. 2016 Aug 17.
Deal LS, Sleeper-Triplett J, DiBenedetti DB, Nelson L, McLeod L, Haydysch EE, Brown TM. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). J Atten Disord. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.